Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/2/2015)... -- The quantum dot market report analyzes the ecosystem of ... the product includes medical devices, display, and others. The others ... energy storage, QD laser, and transistor. The application segment covers ... market. The report also provides the geographic view for major ... Europe , Asia-Pacific (APAC), ...
(Date:9/2/2015)... YORK , Sept. 2, 2015   About ... the most common laboratory technologies that is used for ... antibodies in solution. ELISA test uses various types of ... phosphatases and the result is detected by photometry or ... the treatment of various infectious diseases such as HIV, ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... ... of its efforts to expand awareness of the importance of medical ... America (PhRMA) is announcing today the addition of seven new member ... membership to include an impressive list of progressive companies that represent ...
... ... , ... Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations , ... information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced higher-education,directory, announced ...
Cached Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ProScrub ... easily create back & forth, flicker, repeat, and custom speed effects without the use ... and the speed of effect. ProScrub tools are perfect complements to energetic video ...
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... ... new cases of prostate cancer are reported each year, along with 27,540 deaths attributed to ... lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, ... American Cancer Society. , Prostate cancer is the second leading cause ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership will ... and technical support services to promote LodonalTM in Nigeria. The distribution will become ... efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, Dr ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2
... 2009)Fox Chase Cancer Center researchers report that a combination ... inhibitor of the HER2 receptor (ErbB2) appears active in ... on previous trastuzumab based therapies. More than one-quarter ... their tumors shrink on the combination therapy. , ...
... Laboratories, Inc. (Nasdaq: IDXX ), announced today that ... Annual Growth Stock Conference. Jonathan Ayers, Chairman and CEO, is ... June 9, 2009 at 10:50 a.m. (Central Time), at the ... audio webcast of the presentation through a link on the ...
... Darwin National,Assurance Company, a member company of ... AWH ), today announced that Becky Cox has ... role, Ms. Cox will,be responsible for the continued ... alongside Fred Bautista, Vice,President, Business Development, Healthcare. , ...
... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
... Francisco-to-Los Angeles ride May 31SAN FRANCISCO and LOS ANGELES, ... states and 14 nations will stream out of San ... as participants in the colorful and emotional AIDS/LifeCycle, the ... to raise more than $10 million to support vital ...
... May 28 (HealthDay News) --Should it worry you that there ... , Not especially, when you consider that there are 44 ... , This information comes to you from scientists at the ... same techniques that enabled them to map the human genetic ...
Cached Medicine News:Health News:Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 3Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 3Health News:Study Finds Multitude of Bacteria on Human Skin 2Health News:Study Finds Multitude of Bacteria on Human Skin 3
... ART Aerosol Resistant Tips offer a safe ... Tips are designed for applications such as ... In addition, ART Tips are excellent for ... forensic studies. ART Tips prevent aerosol contaminants ...
Inquire...
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
Medicine Products: